HBM Healthcare Investments AG Stock

Equities

HBMN

CH0012627250

Investment Management & Fund Operators

Market Closed - Swiss Exchange 11:31:28 2024-05-28 am EDT 5-day change 1st Jan Change
207.5 CHF +1.47% Intraday chart for HBM Healthcare Investments AG +3.85% +13.64%
Sales 2025 * 46.1M 50.52M Sales 2026 * 131M 144M Capitalization 1.41B 1.55B
Net income 2025 * 18M 19.73M Net income 2026 * 103M 113M EV / Sales 2025 * 29.5 x
Net cash position 2025 * 53M 58.08M Net cash position 2026 * 75M 82.2M EV / Sales 2026 * 10.2 x
P/E ratio 2025 *
84.5 x
P/E ratio 2026 *
13.9 x
Employees 700
Yield 2025 *
2.75%
Yield 2026 *
2.75%
Free-Float 82.11%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.98%
1 week+4.80%
Current month+11.32%
1 month+11.68%
3 months+17.36%
6 months+17.50%
Current year+13.64%
More quotes
1 week
197.00
Extreme 197
208.50
1 month
183.20
Extreme 183.2
208.50
Current year
155.00
Extreme 155
208.50
1 year
135.20
Extreme 135.2
210.00
3 years
135.20
Extreme 135.2
367.00
5 years
135.20
Extreme 135.2
367.00
10 years
78.65
Extreme 78.65
367.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 01-06-30
Director of Finance/CFO 54 11-10-31
Corporate Secretary 60 -
Members of the board TitleAgeSince
Chairman 68 09-05-31
Director/Board Member 69 21-06-17
Director/Board Member 52 11-12-31
More insiders
Date Price Change Volume
24-05-28 207.5 +1.47% 6 523
24-05-27 204.5 -0.73% 2,979
24-05-24 206 +1.98% 5,718
24-05-23 202 0.00% 3,915
24-05-22 202 +2.02% 4,326

Delayed Quote Swiss Exchange, May 28, 2024 at 11:31 am EDT

More quotes
HBM Healthcare Investments AG is a Switzerland-based venture capital company investing in emerging companies, mainly from the biotechnology and human medicine, diagnostics, as well as medical technology sectors. The Company focuses on unlisted companies, with two-thirds of assets being invested in private companies that offer high value-creation potential. As a holding company, it is involved in the acquisition, disposal and management of a diversified portfolio, as well as in financing and supporting the portfolio firms as a key partner. It focuses on companies with products either at an advanced stage of development or already available on the market. The primary investment areas are Western Europe and the United States. The Company's portfolio includes approximately 25 companies. As of March 31, 2012, the Company had six wholly owned subsidiaries, including three subsidiaries on Cayman Islands, two Barbados-based subsidiaries and a subsidiary in the United States.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
204.5 CHF
Average target price
236 CHF
Spread / Average Target
+15.40%
Consensus

Annual profits - Rate of surprise